Please participate in our anonymous survey to help us improve our website. We are working to ensure we understand all our users needs, ahead of an exciting new redesign.
Take survey
menu

NICE and Waylivra/Volanesorsen

The National Institute of Health and Care Excellence (NICE) will be reviewing waylivra/volanesorsen for the treatment of FCS.  Please share your experience and help us best represent the patient voice in this process. Please get in touch before 31st July 2019 In February 2019 the European Medicines Agency licenced Waylivra / Volanesorsen as “an adjunct […]

The National Institute of Health and Care Excellence (NICE) will be reviewing waylivra/volanesorsen for the treatment of FCS.  Please share your experience and help us best represent the patient voice in this process. Please get in touch before 31st July 2019

In February 2019 the European Medicines Agency licenced Waylivra / Volanesorsen as “an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate”.

You can read more about the EMA’s decision here.